Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.

Saved in:
Bibliographic Details
Title: Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.
Authors: Regillo C; Wills Eye Hospital, Thomas Jefferson University, Mid Atlantic Retina, Philadelphia, Pennsylvania. Electronic address: Cregillo@midatlanticretina.com., Berger B; Austin Clinical Research, Austin, Texas., Brooks L; Southern Vitreoretinal Associates, Tallahassee, Florida., Clark WL; Palmetto Retina Center, Columbia, South Carolina., Mittra R; Retina Consultants of Minnesota, Minneapolis, Minnesota., Wykoff CC; Retina Consultants of Texas, Houston, Texas., Callaway NF; Genentech, Inc., South San Francisco, California; Stanford University Byers Eye Institute, Palo Alto, California., DeGraaf S; Genentech, Inc., South San Francisco, California., Ding HT; Genentech, Inc., South San Francisco, California., Fung AE; Genentech, Inc., South San Francisco, California., Gune S; Genentech, Inc., South San Francisco, California., Le Pogam S; Genentech, Inc., South San Francisco, California., Smith R; Genentech, Inc., South San Francisco, California., Willis JR; Genentech, Inc., South San Francisco, California., Barteselli G; Genentech, Inc., South San Francisco, California.
Source: Ophthalmology [Ophthalmology] 2023 Jul; Vol. 130 (7), pp. 735-747. Date of Electronic Publication: 2023 Mar 02.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1549-4713
DOI:10.1016/j.ophtha.2023.02.024